Calliditas Therapeutics to receive US patent covering Tarpeyo

Calliditas Therapeutics AB, a commercial stage biopharma company, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/100,396 entitled “New Pharmaceutical Compositions.” This Notice of Allowance is expected to result in the issuance of a US patent once administrative processes are completed.

The allowed claims cover a method of treating IgA nephropathy with a composition that encompasses Tarpeyo (budesonide) delayed release capsules, developed under the name “Nefecon”. Calliditas expects the resulting patent will be Orange Book-listable, with an anticipated expiration date in 2043. The patent, when issued, will be Calliditas’ second patent for Tarpeyo in the United States.

Calliditas intends to file corresponding patent applications in additional territories around the world, including Europe and China.

“When issued, our new patent will significantly strengthen Tarpeyo’s intellectual property protection, further improving its unique value proposition, and providing a basis for an active program of extending patent protection of the Nefecon franchise globally,” said CEO Renée Aguiar-Lucander.

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!